Table 2 MA.14 baseline patient and tumor characteristics
From: Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial
Total MA.14 trial | IHC OPN cohort | Plasma OPN cohort | ||||
|---|---|---|---|---|---|---|
Number | % | Number | % | Number | % | |
Total | 667 | 100 | 462 | 100 | 388 | 100 |
Age at allocation (yrs) | ||||||
<60 | 329 | 49 | 220 | 48 | 193 | 50 |
≥60 | 338 | 51 | 242 | 52 | 195 | 50 |
Race | ||||||
Caucasian | 644 | 97 | 445 | 96 | 375 | 97 |
Not Caucasian | 23 | 3 | 17 | 4 | 13 | 3 |
Performance status (ECOG) | ||||||
0, unknown | 520 | 78 | 362 | 78 | 305 | 79 |
1, 2 | 147 | 22 | 100 | 22 | 83 | 21 |
T pathologic classification | ||||||
1, in situ | 389 | 58 | 269 | 58 | 240 | 62 |
2, 3A, 4, unknown | 278 | 42 | 193 | 42 | 148 | 38 |
N pathologic classification | ||||||
0 | 352 | 53 | 243 | 53 | 206 | 53 |
1, 2, unknown | 315 | 47 | 219 | 47 | 182 | 47 |
Breast surgery type | ||||||
Total mastectomy | 260 | 39 | 174 | 38 | 146 | 38 |
Other, segmental | 407 | 61 | 288 | 62 | 242 | 62 |
Number of positive nodes | ||||||
0 | 352 | 53 | 243 | 53 | 206 | 53 |
1 to 3, 4+, unknown | 315 | 47 | 219 | 47 | 182 | 47 |
ER/PR status | ||||||
Negative, unknown | 62 | 9 | 33 | 7 | 33 | 9 |
Positive | 605 | 91 | 429 | 93 | 355 | 91 |
Adjuvant chemotherapy | ||||||
None | 445 | 67 | 312 | 68 | 236 | 61 |
Concurrent, sequential | 222 | 33 | 150 | 32 | 152 | 39 |
Tumor grade* | ||||||
Unknown | NA | 0 | 0 | 84 | 22 | |
1 | NA | 74 | 16 | 48 | 12 | |
2 | NA | 232 | 50 | 150 | 39 | |
3 | NA | 156 | 34 | 106 | 27 | |
Histology* | ||||||
No special type | NA | 446 | 97 | 290 | 75 | |
Special type (unknown) | NA | 16 | 3 | 14 (84) | 4 (22) | |
Lymphovascular invasion* | ||||||
Unknown | NA | 0 | 0 | 84 | 22 | |
No | NA | 414 | 90 | 274 | 71 | |
Yes | NA | 48 | 10 | 30 | 8 | |